Stockscreener 앱 받기
0.9133
3.45%
-0.0326
전일 마감가:
$0.9459
열려 있는:
$0.95
하루 거래량:
291.72K
Relative Volume:
0.82
시가총액:
$44.12M
수익:
-
순이익/손실:
$-77.90M
주가수익비율:
-0.5663
EPS:
-1.6127
순현금흐름:
$-30.38M
1주 성능:
-8.21%
1개월 성능:
-16.21%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.905
$0.95
1주일 범위
$0.905
$1.05
52주 변동 폭
$0.8564
$2.0901
Filana Therapeutics Inc Stock (FLNA) Company Profile
명칭
Filana Therapeutics Inc
전화
512-501-2444
주소
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN
Compare FLNA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FLNA
Filana Therapeutics Inc
|
0.9133 | 45.09M | 0 | -77.90M | -30.38M | -1.6127 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Filana Therapeutics Inc Stock (FLNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-27 | 개시 | B. Riley Securities | Buy |
| 2021-02-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-01-10 | 재확인 | Maxim Group | Buy |
모두보기
Filana Therapeutics Inc 주식(FLNA)의 최신 뉴스
Cassava Sciences Securities Litigation Ruling: Court Denies Ugarte Dismissal Motions Without Prejudice While Awaiting Fifth Circuit Ruling - TipRanks
Law firm investigates Filana Therapeutics officers for possible shareholder rights breaches - pluang.com
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Filana Therapeutics, Inc. (NASDAQ: FLNA) Share Price, FLNA Stock News, FLNA Share Price & Updates - Kalkine
Weekly Recap: FDA clinical hold on TSC trial and Q2 2026 cash $82.7M - TradingView
Filana Therapeutics Q2 EPS beats estimate, loss narrows 81% - scanx.trade
Filana Therapeutics, Inc. Revenue Breakdown – NASDAQ:FLNA - TradingView
Filana Therapeutics (FLNA) AGM 2026 Summary - Quartr
Filana Therapeutics (FLNA) Q4 2025 earnings summary - Quartr
Filana Therapeutics (FLNA) Slides 5% as Bearish Momentum Builds; Key Support at $1.04 in FocusATR Stop - dars.gov.et
MSN Money - MSN
FLNA Price Today: Filana Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Despite Stock SlideEPS Surprise History - dars.gov.et
FLNAFilana Therapeutics Inc Short Interest - Finviz
FLNA Should I Buy - Intellectia AI
Price to sales forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Price to book forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Filana Therapeutics, Inc. Actuals & Estimates (NASDAQ:FLNA) - TradingView
Filana Therapeutics, Inc. Actuals & Estimates (TRADEGATE:PX91) - TradingView
Enterprise value to revenue forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Price to earnings forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
FLNA Forecast — Price Target — Prediction for 2027 - TradingView
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
Filana Therapeutics (FLNA) Holds Near Support Amid Modest DeclineForce Index - dars.gov.et
Filana Therapeutics Shareholders Back Board, Compensation Plans - The Globe and Mail
FLNA Q3 2025 Earnings: Narrower Loss Beats Street, But Shares Slide on UncertaintyLow Estimate Range - newsline.com
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Trend Analysis - newsline.com
Filana Therapeutics, Inc. 8-K Filing Details: Amended 2018 Omnibus Incentive Plan and Company Information (June 2026) – Minichart - Minichart
Filana Therapeutics (FLNA) investors back directors, plan changes and auditor - Stock Titan
Filana Therapeutics (FLNA) Slips 4.6% as Biotech Sector Headwinds Test SupportConversion Trade - newsline.com
FLNA: All proposals passed as the company focuses on resolving the FDA clinical hold for its TSC program - TradingView
Filana Therapeutics (FLNA) Surges Over 8%—Testing Key Resistance at $1.50Beta Neutral Pair - newsline.com
Filana Therapeutics (FLNA) Edges Higher as Stock Tests Key Resistance LevelTrend Following Picks - newsline.com
Filana Therapeutics (FLNA) Slips 4.5% as Stock Approaches Key Support LevelIV Rank - newsline.com
Data I/O And 2 Other Promising Penny Stocks To Watch - simplywall.st
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Stock RallyEarnings Surprise Stocks - The Legal Advocate
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Propels Shares HigherEarnings Volatility Report - dars.gov.et
Filana Therapeutics (FLNA) Gains 6.38% as Biotech Momentum BuildsPCR Spike - newsline.com
FLNA Reinstated by Maxim Group -- Price Target Announced at $5.0 - GuruFocus
FLNA Reinstated by Maxim Group -- Price Target Announced at $5.00 - GuruFocus
Filana Therapeutics (FLNA) Posts Modest Gains Amid Broader Biotech ResilienceExpert Breakout Alerts - Newser
Filana Therapeutics (FLNA) Stock: Up +0.80%, Key Resistance at $1.32 2026-05-21IPO Entry Watch - The Legal Advocate
Filana Therapeutics Inc (FLNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):